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Lysine-Specific Demethylase 1 (LSD1, KDM1A) func-
tions as a transcriptional corepressor through deme-
thylation of histone 3 lysine 4 (H3K4) but has a coacti-
vator function on some genes through mechanisms
that are unclear. We show that LSD1, interacting with
CoREST, associates with and coactivates androgen
receptor (AR) on a large fraction of androgen-stimu-
lated genes. A subset of these AR/LSD1-associated
enhancer sites have histone 3 threonine 6 phosphory-
lation (H3T6ph), and these sites are further enriched
for androgen-stimulated genes. Significantly, despite
its coactivator activity, LSD1 still mediates H3K4me2
demethylation at these androgen-stimulated en-
hancers. FOXA1 is also associated with LSD1 at AR-
regulated enhancer sites, and a FOXA1 interaction
with LSD1 enhances binding of both proteins at
these sites. These findings show that LSD1 functions
broadly as a regulator of AR function, that it maintains
a transcriptional repression function at AR-regulated
enhancers through H3K4 demethylation, and that it
hasadistinctAR-linkedcoactivator functionmediated
by demethylation of other substrates.
INTRODUCTION
Androgen receptor (AR) is highly expressed in prostate cancer
(PCa) cells and plays a pivotal role in PCa through transactiva-1618 Cell Reports 9, 1618–1627, December 11, 2014 ª2014 The Auttion of multiple genes (Green et al., 2012; Yuan et al., 2014).
Patients with metastatic PCa are treated with androgen depriva-
tion therapy (ADT) to block AR activity, but the tumors invariably
relapse (castration-resistant prostate cancer [CRPC]). Signifi-
cantly, AR expression is increased in CRPC and most AR-
stimulated genes are highly expressed, indicating that AR
transcriptional activity has been substantially restored (Yuan
et al., 2014). The recent clinical success of abiraterone
(CYP17A1 inhibitor that further suppresses androgen synthesis)
and enzalutamide (AR antagonist) has confirmed that AR, stim-
ulated by residual androgens, is a driver of tumor growth in
CRPC (de Bono et al., 2011; Ryan et al., 2013; Scher et al.,
2012). However, patients treated with these agents still gener-
ally relapse within 1–2 years, and high levels of AR and of AR-
regulated genes in many of these relapsed tumors indicate
that AR activity has again been restored. Therefore, there is still
a pressing need to better understand AR transcriptional mech-
anisms in order to develop further approaches for blocking or
modulating its activity.
AR also has a transcriptional repression function that is depen-
dent on lysine-specific demethylase 1 (LSD1, KDM1A) (Cai et al.,
2011). Best characterized as a transcriptional repressor, LSD1
associates tightly with CoREST and demethylates enhancer-
associated H3K4me1,2 (Lee et al., 2005; Shi et al., 2004, 2005;
You et al., 2001). The histone deacetylases HDAC1 and 2 are
usually associated with the LSD1-CoREST complex and can
further suppress gene transcription. Nonetheless, in contrast to
its well-established corepressor function, LSD1 has been found
to coactivate several transcription factors including AR on a
small set of genes (Garcia-Bassets et al., 2007; Metzger et al.,
2005; Wang et al., 2007a; Wissmann et al., 2007; Yatim et al.,hors
2012), where phosphorylation of H3T6 and H3T11 may switch
LSD1 substrate specificity from H3K4me1,2 to H3K9me1,2
(Metzger et al., 2008, 2010). However, the extent to which
LSD1 functions as a general regulator of AR transcriptional activ-
ities and the roles of histone phosphorylation and demethylation
inmediating its AR coactivator function remain to be established.
In this study, to systematically assess the role of LSD1 in
regulating AR functions, we performed an integrated analysis
with LSD1, AR, and FOXA1 chromatin immunoprecipitation
sequencing (ChIP-seq), and with gene expression arrays. Our
results demonstrate that LSD1 functions broadly as a coactiva-
tor at AR-stimulated enhancers but retains its H3K4me1,2
demethylase activity at these sites. This activity may provide
negative feedback to suppress gene expression in the absence
of androgen and prevent the aberrant activation of cryptic AR
enhancers. Moreover, it indicates that androgen-dependent
LSD1 coactivator function is mediated by demethylation of other
histone or nonhistone substrates.
RESULTS
LSD1-Positive AR Binding Sites Are Associated with
Androgen-Stimulated Genes
Using ChIP-seq for LSD1 in androgen-treated PCa cells
(LNCaP), in combination with previous ChIP-seq data for AR
and gene expression arrays (Cai et al., 2011; Lupien et al.,
2008; Wang et al., 2007b, 2009b; Yu et al., 2010), we found
that 20% of LSD1 and AR sites were overlapping (Figure 1A).
AR binding sites were enriched 3-fold among genes that
were increased after 4 or 16 hr of dihydrotestosterone (DHT)
treatment, with56% of DHT-stimulated genes having AR bind-
ing sites (Figure 1B). Similarly, LSD1 binding sites were enriched
2-fold among DHT-stimulated genes, with 42% having LSD1
binding sites (Figure 1C). AR binding was not clearly enriched
among DHT-repressed genes (Figure 1B), whereas LSD1 bind-
ing was enriched 1.5-fold on these genes, and 29% had
LSD1 binding sites (versus 20% background) (Figure 1C). How-
ever, direct examination of ChIP-seq data for LSD1-occupied
sites inmanyDHT-repressed genes showed that ARwas binding
but was below the peak threshold (Figure S1A), possibly reflect-
ing weaker AR binding or lower affinity of the antibodies for AR at
these sites.
LSD1+ as compared to LSD1 AR binding sites were further
enriched among DHT-stimulated genes (5- to 7-fold versus
2-fold) (Figure 1D), and Binding and Expression Target Anal-
ysis (BETA) (Wang et al., 2013) confirmed that LSD1+ AR sites
were significantly enriched for these genes (Figure S1B). Overall,
among the genes stimulated by DHT after 4 hr that had AR bind-
ing sites (56%), LSD1 was associated with the AR site at
39% (22%/56%). As expected, AR+/LSD1+ sites were en-
riched for AR and FOXA1 binding motifs, whereas AR/LSD1+
sites were enriched for repressors such as REST or NF1, as
well as for FOXA1 (Figure 1D; Table S1). LSD1 binding intensity
was similar between AR-positive and -negative sites (Figures
S1C and S1D), but AR-negative LSD1 sites were enriched in
promoter regions (Figure S1E). Overall these findings showed
that LSD1 was broadly associated with AR at androgen-stimu-
lated genes.Cell ReLSD1 Functions as a Coactivator on a Large Fraction of
AR-Stimulated Genes
Transcript profiling in LSD1 versus control small interfering RNA
(siRNA)-treated cells next showed that LSD1-activated genes
were enriched for cell-cycle and lipid synthesis pathways,
whereas LSD1-suppressed genes were enriched for apoptosis
(Figure 1E; Table S1). Significantly, androgen-stimulated genes
were broadly decreased by LSD1 siRNA (Figure 1F). AR-positive
LSD1 binding sites were also enriched for LSD1-activated
genes, whereas AR-negative LSD1 binding sites were enriched
for LSD1-suppressed genes (Figure S1F), consistent with LSD1
functioning generally as a corepressor at AR-negative sites, and
indicating that its coactivation function is linked to AR. LSD1 in-
hibitors (pargyline and S2101) also impaired, but did not totally
eliminate, androgen-stimulated expression of multiple AR-acti-
vated genes (Figure 1G), further indicating that LSD1 contributes
to AR transcriptional activity but may not be absolutely required.
AR+/LSD1+ sites in VCaP cells similarly showed enrichment for
AR-stimulated genes, and LSD1 RNAi and inhibitors similarly
decreased androgen-stimulated expression of these genes
(Figures S1G–S1M). Finally, DNase sequencing (DNase-seq)
(He et al., 2012) showed that AR+/LSD1+ sites were DNase
hypersensitive (DNase-HS) and were more sensitive than AR+/
LSD1 sites (Figure 1H), further indicating these sites are AR-
regulated transcriptional enhancers. DNase-HS was increased
by DHT at AR binding sites (Figures 1H and S1N), consistent
with AR-mediated loss of a central nucleosome overlapping
the AR binding site (Andreu-Vieyra et al., 2011; He et al.,
2010). Together these data indicated that whereas LSD1 is a
corepressor at most sites, it functions broadly as a coactivator
on AR-regulated transcriptional enhancers.
Because the LSD1 transcription profiling indicated that LSD1
might both stimulate PCa growth through its AR coactivator
functions and suppress apoptosis through AR-independent
mechanisms, we examinedwhether LSD1 activity was increased
in PCa. In three cohorts, expression of LSD1-activated genes
(genes with LSD1 binding sites that were decreased by LSD1
siRNA) was increased in PCa versus normal prostate, whereas
LSD1-suppressed genes were decreased (Figure 1I). Higher
LSD1mRNA alsowas significantly associated with lower survival
in one patient cohort, whereas there was a similar trend in
two other cohorts that did not reach statistical significance
(Figure S1O).
LSD1 Mediates H3K4 Demethylation on AR-Stimulated
Genes
To assess LSD1 effects on H3K4 and K9 methylation, we next
examined AR+/LSD1+ binding sites in a series of AR-stimulated
genes (Figure S2A). As expected, FOXA1 was bound to these
sites prior to DHT treatment, and AR binding was stimulated
by DHT (Figure S2B). FOXA1 and DHT-stimulated AR
binding were also observed at AR+/LSD1 sites (CREG1 and
KIAA0040 genes), but not at AR/LSD1+ sites in three other
genes that were not androgen-regulated (HMGB2, HHLA3,
SH2B1) (Figure S2C). DHT decreased H3K9me1,2 at each of
the AR+/LSD1+ sites (Figure S2D), consistent with previous
data indicating that LSD1may switch from H3K4 to H3K9 deme-
thylation at AR-regulated enhancers (Metzger et al., 2005, 2008,ports 9, 1618–1627, December 11, 2014 ª2014 The Authors 1619
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2010; Wissmann et al., 2007). However, H3K4me1,2 was also
decreased by DHT at each AR+/LSD1+ site (Figure S2D), but
not at control AR/LSD1+ or AR+/LSD1 sites (Figure S2C,
right panel), suggesting that LSD1 still had H3K4 demethylation
activity at AR+/LSD1+ sites.
Consistent with previous data (Andreu-Vieyra et al., 2011; He
et al., 2010), ChIP showed that histone 3 (H3) binding was also
decreased by DHT at each AR binding site (Figure S2D), indi-
cating that the decrease in H3K4 and H3K9 methylation at
AR+/LSD1+ sites may in part reflect loss of the central nucleo-
some rather than H3 demethylation. Therefore, to determine if
decreasedmethylation reflects nucleosome loss, we next exam-
ined the effects of LSD1 inhibitors on AR and H3 binding, and on
H3 methylation. Blocking LSD1 with pargyline prevented DHT-
stimulated H3K4me2 loss at all sites examined except the
PLZF-ARE (Figure 2A, upper-left panel) but did not impair
DHT-stimulated AR binding or H3 loss (Figure 2A, upper-right
and lower-left panels). This result indicates that nucleosome
loss does not substantially contribute to the overall decrease in
H3K4me2 methylation, perhaps reflecting preferential loss of
unmethylated central nucleosomes.
LSD1 inhibition similarly impaired the DHT-stimulated
decrease in H3K9me1, although it had varying effects on basal
H3K9me1 (Figure 2A, lower right panel). Significantly, pargyline
also increased H3K9me1 at AR-negative LSD1 sites, including
REST sites where LSD1 functions as a corepressor, indicating
that H3K9 demethylation by LSD1 may not be unique to AR-
stimulated genes (Figure S2E). Another LSD1 inhibitor (S2101)
(Figure S2F) or LSD1 siRNA (Figure S2G) similarly did not impair
AR binding, and comparable results for AR, H3, H3K4me2, and
H3K9me1 were also obtained in VCaP cells with transient or
stable knockdown of LSD1 (Figures S2H and S2I). Collectively,
these results show that LSD1 retains its H3K4 demethylation
activity at these AR-regulated enhancers.
We next used ChIP-seq to globally assess H3K4me2 in
response to DHT (He et al., 2010). AR+/LSD1+ sites had higher
basal H3K4me2 compared to AR+/LSD1 sites (Figure 2B),
consistent with the AR+/LSD1+ sites being enhancers. DHT stim-
ulated an increase in H3K4me2 at flanking nucleosomes at AR+/
LSD1 sites, indicating AR recruitment of a histone methyltrans-
ferase (Gaughan et al., 2011; Ko et al., 2011). Significantly, in
addition to lower basal H3K4me2, the AR+/LSD1 sites have
lower DNase-HS and are less enriched for androgen-stimulatedFigure 1. LSD1 Functions Broadly as an AR Coactivator
(A) Overlap between AR and LSD1 ChIP-seq in LNCaP cells treated for 4 hours
(B) AR binding site enrichment for genes increased after 4 or 16 hr DHT sti
(DHT_16h_down).
(C) LSD1 binding site enrichment for expression of androgen-regulated genes.
(D) Enrichment analysis of AR+/LSD1+, AR+/LSD1, or AR/LSD1+ sites for andr
each subset of binding sites are shown. Note: the percentage labeled on the bar
that have the respective binding site.
(E) LNCaP cells transfected with nontarget control (siNTC) or LSD1 siRNA (siLSD1
done on 284 LSD1-activated genes and 223 LSD1-suppressed genes (cutoff 2-f
(F) Ratio of expression in siNTC versus in siLSD1-treated cells (log scale) is plott
(G) qRT-PCR in LNCaP cells treated with LSD1 inhibitor pargyline (1 mM) or S21
(H) Mean DNase-HS signals in DHT-stimulated versus vehicle-treated LNCaP ce
(I) Box plot for expression of direct LSD1-regulated genes in PCa versus benign
Data in bar graphs represent means ± SD of at least three biological repeats. Se
Cell Regenes (see Figures 1D and 1H), indicating they may be cryptic
AR-regulated enhancers. In contrast, DHT treatment at AR+/
LSD1+ sites did not increase H3K4me2 marks over the positions
of the flanking nucleosomes and caused a loss of H3K4me2 over
the central nucleosome (Figures 2B and S2J). Collectively, these
results showed that LSD1, despite functioning as a coactivator at
AR-regulated enhancers, retains its H3K4 demethylation activity
that is associated with repression.
LSD1-CoREST Complex Is Associated with LSD1
Coactivator Function
Because LSD1 H3K4 demethylation activity is enhanced by
CoREST (Lee et al., 2005; Shi et al., 2005), we next askedwhether
LSD1 was associated with the CoREST repressor complex at AR
enhancers.Coimmunoprecipitationconfirmed thestrongassocia-
tion of LSD1 with CoREST, HDAC1, and HDAC2 in LNCaP (Fig-
ure 2C) and VCaP (Figures S2K and S2L) cells, and by ChIP we
found that CoREST binding to a series of AR-regulated enhancers
correlated with LSD1 binding (Figure 2D). Interestingly, DHT
caused a reduction of LSD1-CoREST binding at many of these
sites, possibly reflecting subsequent chromatin remodeling. Sig-
nificantly, CoREST siRNA mimicked the effects of LSD1 siRNA in
decreasing expression of AR-stimulated genes (Figure 2E), further
supporting a coactivator function for the LSD1-CoREST complex.
H3T6ph-Positive AR/LSD1 Sites Are Markedly Enriched
for Androgen-Stimulated Genes
Although these data indicated that LSD1 generally retains its
H3K4 demethylase activity at AR-regulated enhancers, this
activity may be impaired by H3T6ph at a subset of sites (Metzger
et al., 2005, 2008, 2010). Therefore, we next performed H3T6ph
ChIP-seq to globally assess the association of H3T6ph with AR
and LSD1 binding, with gene expression, and with H3K4 methyl-
ation. Approximately 12% of total AR binding sites and 20% of
AR+/LSD1+ sites overlapped with H3T6ph sites (Figures 3A
and 3B). Significantly, although only a minority of DHT-stimu-
lated genes had H3T6ph-positive AR sites (14%–20%), these
H3T6-positive sites were markedly enriched (12-fold) for
DHT-stimulated genes (Figure 3C). Moreover, H3T6ph-positive
AR+/LSD1+ sites were even further enriched for DHT-stimulated
genes (18-fold) (Figure 3D). Finally, consistent with a previous
report that androgen stimulates H3T6 phosphorylation through
activating PKCb1 (Metzger et al., 2010), treating cells with a(hr) with 10 nM DHT.
mulation (DHT_4h_up, DHT_16h_up) or suppressed genes after 16 hr DHT
ogen-regulated genes. High-frequency motifs and corresponding proteins on
graph of (B)–(D) indicates the percentage of DHT-induced or -repressed genes
) in presence of DHT were subjected to RNA-seq. Gene ontology analysis was
old).
ed for DHT-regulated genes.
01 (100 mM) for 24 hr with/out DHT.
lls at the indicated sites.
samples in three independent cohorts from Oncomine database.
e also Figure S1 and Table S1.
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PKCb inhibitor (BIM1) blocked the DHT-stimulated increase in
H3T6ph and impaired the DHT stimulation of a panel of AR-regu-
lated genes (Figures S3A and S3B). Together these findings indi-
cate that H3T6 phosphorylation is linked to LSD1 coactivation of
AR transcriptional activity.
DNase-HS also was increased at H3T6ph-positive versus -
negative AR+/LSD1+ sites (Figure 3E), further linking H3T6ph to
transcriptional activation. In contrast, DNase-HS at H3T6-posi-
tive AR+/LSD1 sites was low (Figure 3E, right panel), whereas
DNase-HS at H3T6ph-positive versus -negative LSD1 sites was
increased (Figure S3C), further supporting a link between LSD1
and H3T6ph. Similarly to DNase-HS, basal (prior to DHT stimula-
tion) H3K4me2 was increased at H3T6ph-positive versus -nega-
tive AR+/LSD1+ sites (Figure 3F). However, DHT still caused
a decrease in H3K4me2 methylation at these sites, versus an
increase at LSD1-negative AR+/H3T6ph+ sites (Figure 3F). The
DNase-HSandH3K4me2ChIP-seqdata arequantified inFigures
S3D and S3E. We also assessed H3T6ph and H3K4me2 deme-
thylation at a series of individual AR+/LSD1+ sites. These sites
in four of six genes had high H3T6ph (PSA, NKX3.1, PLZF, and
SGK3) (Figure S3F), but all underwent H3K4me2 demethylation
in response to DHT (see Figure 2A). Finally, inhibition of H3T6
phosphorylation with BIM1 did not enhance the androgen-stimu-
lated demethylation of H3K4 or impair the demethylation H3K9
(Figure S3G). Together, these findings indicate that H3T6ph
does not abrogate H3K4 demethylation by LSD1.
FOXA1 Associates with LSD1 and Mediates Its
Recruitment to AR-Dependent Enhancers
As FOXA1 is a pioneer factor for AR-regulated enhancers,
we next performed FOXA1 ChIP-seq and found substantial over-
lap (42%) between LSD1 and FOXA1 sites (Figure 4A). Signifi-
cantly, AR+/LSD1+/FOXA1+ sites were more enriched (9-fold)
among AR-activated genes than AR+/LSD1+/FOXA1 (5-fold)
or AR+/LSD1/FOXA1+ (5-fold) sites (Figure 4B), indicating
that LSD1 and FOXA1 may collaborate to regulate AR activity.
Similarly, AR+/LSD1+/FOXA1+ sites were also more enriched
for LSD1-activated genes than AR+/LSD1+/FOXA1 or AR+/
LSD1/FOXA1+ sites (Figure S4A). Finally, FOXA1-positive
AR+/LSD1+ sites had increased basal DNase-HS versus
FOXA1-negative AR+/LSD1+ sites (Figure 4C), consistent with
the FOXA1-positive sites being enhancers, although DHT
increased DNase-HS at all sites (Figure S4B).
Coimmunoprecipitations in LNCaP cells indicated an
association between FOXA1 and the LSD1-CoREST complex
(Figure 4D). This was not mediated by AR, as we could also co-
precipitate FOXA1 with transfected FLAG-LSD1 in AR-negative
PC3 cells, although the interaction could still be indirect andFigure 2. LSD1 Demethylates H3K4me2 on AR-Regulated Enhancers
(A) ChIP-qPCR for AR, H3, H3K4me2, or H3K9me1 in LNCaP cells pretreated w
(B) Mean of H3K4me2 ChIP-seq signals in DHT-stimulated versus vehicle-treate
LSD1 peak for AR-negative LSD1 sites.
(C) Co-IP of LSD1 or CoREST in LNCaP cells treated with/out DHT for 6 hr.
(D) ChIP-qPCR for LSD1 or CoREST at androgen-stimulated enhancer sites a
DHT for 4 hr.
(E) qRT-PCR in LNCaP cells transfected with nontargeting control (NTC), LSD1,
Data in bar graphs represent means ± SD of at least three biological repeats. Se
Cell Rethrough another protein or long noncoding RNA (Figure 4E).
We next used FOXA1 siRNA to determine whether basal (prior
to DHT treatment) LSD1 binding to AR+/FOXA1+ sites in AR-
regulated enhancers was FOXA1 dependent. Immunoblotting
confirmed that FOXA1 siRNA markedly decreased FOXA1, but
not LSD1orCoREST (Figure 4F). Significantly, ChIP then showed
that FOXA1 siRNA decreased basal LSD1 binding to a similar
extent as CoREST siRNA at a series of AR/LSD1-regulated en-
hancers (Figure 4G). In the converse experiment, we treated cells
with LSD1siRNAand foundamarkeddecrease in FOXA1binding
at these enhancers (Figure 4H). Collectively, these results indi-
cate that FOXA1 may initially recruit the LSD1-CoREST complex
to androgen-regulated enhancers, where FOXA1-LSD1 interac-
tionsmay then stabilize the binding of both proteins to chromatin.
The LSD1-CoREST complex may then function through HDACs
to suppress basal transcription, and by H3K4 demethylation as
a negative-feedback mechanism to close any aberrantly opened
cryptic enhancers. Indeed, we found that HDAC1 and 2, which
are components of the LSD1-CoREST complex, are associated
with AR-regulated enhancers even in the absence of AR (Fig-
ure S4C), and that HDAC inhibition increased basal expression
of AR-stimulated genes (Figure S4D).
Two recent studies found that FOXA1 RNAi caused a marked
redistributionofAR,with lossofARbindingatmanysitesandgen-
eration of new binding sites (Sahu et al., 2011;Wang et al., 2011).
Using these data (Wang et al., 2011) in conjunction with our AR
andLSD1ChIP-seqdata,we found that60%ofARbinding sites
were lost after FOXA1knockdown,but that this losswasonly39%
for theLSD1-positiveARbinding sites (FigureS4E).Moreover, AR
binding prior to FOXA1 siRNA was higher at the 61% of LSD1-
positive AR sites that were retained versus the 39% that were
lost, and AR binding at these 61% retained sites increased after
FOXA1 siRNA (Figure S4F). H3K4me1 and H3K4me2 were also
decreased after FOXA1 siRNA at these 61% of sites with re-
tained/increased AR binding (Figure S4F). In conjunction with
the above results, these findings suggest that LSD1may stabilize
AR binding directly, or indirectly through enhanced binding of
residual FOXA1. Although we found that short-term inhibition or
depletion of LSD1 did not impair AR binding (see Figures 2 and
S2), we are currently exploring the long-term effect of LSD1
silencing on AR binding and enhancer activity through FOXA1-
dependent or -independent mechanisms.
DISCUSSION
The H3K4me1,2 demethylase activity of LSD1 in LSD1-CoREST
repressor complexes is well established, but LSD1 also can
mediateH3K9me1,2 demethylation and function as a coactivatorith pargyline for 6 hr and then treated with/out DHT for 4 hr.
d LNCaP cells. The center of curve was aligned with the center of AR peak or
nd an AR/LSD1+ site in the HMGB2 gene in LNCaP cells treated with/out
or CoREST siRNA with/out DHT (*18-fold).
e also Figure S2.
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Figure 3. LSD1 Mediates H3K4me2 Demethylation at H3T6ph-Positive AR and LSD1 Sites
(A) Overlap of AR and H3T6ph ChIP-seq in LNCaP cells treated with DHT.
(B) Overlap between AR+/LSD1+ sites and H3T6ph peaks.
(C and D) Enrichment for androgen-stimulated genes at AR and H3T6ph overlapping sites (C) and at AR, LSD1, and H3T6ph overlapping sites (D).
(E and F) Mean DNase-HS signals (E) or mean H3K4me2 ChIP-seq signals (F) at indicated sites in LNCaP cells stimulated with DHT or vehicle.
See also Figure S3.for several AR-stimulated genes (Metzger et al., 2005;Wissmann
et al., 2007), and an H3T6 and T11 phosphorylation-mediated
switch from H3K4 to K9 demethylation may contribute to
this LSD1 coactivator function (Metzger et al., 2008, 2010). This
study shows that LSD1 is broadly associated with AR-regulated
enhancers and functions as a coactivator for AR at these sites,
and that H3T6ph-positive AR+/LSD1+ sites are further enriched
for AR-activated genes. However, H3K4me2 ChIP studies
showed that androgen-stimulatedH3K4demethylationpersisted1624 Cell Reports 9, 1618–1627, December 11, 2014 ª2014 The Autat AR+/LSD1+ sites, including H3T6ph-positive AR+/LSD1+ sites.
Moreover, LSD1-mediated H3K9 demethylation could also be
observed at AR-independent LSD1 sites. Therefore, whereas
some bias in favor of H3K9 versus H3K4 demethylation may
contribute to LSD1 coactivator function, these findings indicate
that LSD1 has dual corepressor and coactivator functions
at androgen-stimulated genes, with the latter coactivator func-
tion being mediated by demethylation of additional nonhistone
substrates.hors
Figure 4. FOXA1 Associates with LSD1-CoREST Complex at AR-Stimulated Enhancers
(A) Overlap between AR, FOXA1, and LSD1 binding sites in LNCaP cells stimulated with DHT or vehicle.
(B) Enrichment analysis of AR+/LSD1+/FOXA1+, AR+/LSD1+/FOXA1, or AR+/LSD1/FOXA1+ sites for androgen-regulated genes.
(C) Mean DNase-HS signals at indicated sites in LNCaP cells treated with DHT or vehicle.
(D) Anti-FOXA1 immunoprecipitated proteins from LNCaP cells treated with/out DHT for 6 hr were immunoblotted as indicated.
(E) FOXA1 coimmunoprecipitation with anti-FLAG from FLAG-LSD1- and FOXA1-transfected PC-3 cells.
(legend continued on next page)
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H3K4 methylation and FOXA1 binding serve to initially expose
enhancer binding sites prior to ligand-stimulated binding of ste-
roid receptors (Carroll et al., 2005; Lupien et al., 2008). This study
shows that FOXA1 interacts with the LSD1-CoREST complex
and may mediate its initial recruitment to AR-regulated en-
hancers. Conversely, LSD1 binding at these sites can then stabi-
lize FOXA1 binding. LSD1 may then mediate demethylation of
H3K4me2 at these sites as a negative-feedback mechanism to
close enhancers if their H3K4 methylation and FOXA1 binding
is not reinforced by AR, thereby preventing aberrant enhancer
activation. AR may reinforce FOXA1 binding through a direct
interaction, and indirectly by recruitment of H3K4 methyltrans-
ferases and HATs, the latter which may impair LSD1 activity
through H3 acetylation. Finally, HDACs associated with the
LSD1-CoREST complex may also serve to suppress gene
expression prior to androgen stimulation and AR binding.
We hypothesize that the AR coactivator function of LSD1 re-
flects demethylation of one or more nonhistone substrates, but
the identity of any novel LSD1 substrates and the functional
consequences of their demethylation remain unclear. Mass
spectrometry has identified methylated lysines in AR, but there
are no data showing that they are regulated by LSD1 (Gaughan
et al., 2011; Ko et al., 2011). Recent studies have identified
nonhistone LSD1 substrates, including transcription factors,
but none are known to have roles in AR-mediated transcription
(Cho et al., 2011; Huang et al., 2007; Kontaki and Talianidis,
2010; Wang et al., 2009a). LSD1, possibly through interactions
with long noncoding RNA, may also contribute to the targeting
of AR-stimulated genes to specific nuclear domains that are en-
riched in transcriptional cofactors (Hu et al., 2008). Importantly,
our data show that inhibiting or depleting LSD1 acutely does
not prevent AR binding to chromatin or displacement of the
central nucleosome overlapping the AR binding site, indicating
that any critical LSD1 substrates are functioning downstream
of these initial steps. Identification of these substrates may allow
for the selective abrogation of LSD1 coactivator function and
provide a novel approach for PCa therapy.
EXPERIMENTAL PROCEDURES
RT-PCR, Immunoblotting, and Coimmunoprecipitation
Quantitative real-time RT-PCR amplification was done with TaqMan one-step
RT-PCR reagents and results were normalized to coamplified 18S RNA or
GAPDH. For immunoblotting, cells were lysed with RIPA buffer with protease
inhibitors. For immunoprecipitation assay, equal amounts of protein (1–5 mg)
were mixed with 20–50 ml of antibody-conjugated agarose beads. Antibodies,
primers, and probes are listed in Supplemental Experimental Procedures sec-
tion. Gels shown are representative of at least three independent experiments.
Chromatin Immunoprecipitation
Cells were formalin fixed, lysed, and sonicated to break the chromatin into
500 bp fragments. ChIP-grade antibodies were used to precipitate chro-
matin fragments from cell extracts. We used real-time quantitative PCR
(SYBR green) to amplify the DNA fragment in the antibody precipitated DNA
and the unprecipitated input DNA to calculate the percentage. ChIP-seq(F) LNCaP cells transfected with siNTC or siRNA against FOXA1 or CoREST wer
(G and H) LNCaP cells were transfected with siNTC or siRNA against FOXA1 or C
ChIP-qPCR for LSD1 (G) or FOXA1 (H) at androgen-stimulated enhancers.
Data in bar graphs represent means ± SD of at least three biological repeats. Se
1626 Cell Reports 9, 1618–1627, December 11, 2014 ª2014 The Autwas done with higher intensity sonication of cell lysates and sequenced with
Illumina Genome Analyzer or High-seq. Significantly (p < 1 3 105) enriched
regions were detected using MACS. For all integrated analyses, we searched
binding sites around 20 kb from transcriptional starting site.
Statistical Analyses
Data in bar graphs represent means ± SD of at least three biological repeats.
Statistical analysis was performed by Student’s t test. A p value < 0.05 was
considered to be statistically significant.
ACCESSION NUMBERS
The GEO accession for LSD1, H3T6ph, and FOXA1 ChIP-seq and LSD1 siRNA
RNA-seq data is GSE52201.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.11.008.
AUTHOR CONTRIBUTIONS
C.C., H.H.H., X.S.L., M.B., and S.P.B., designed the study. C.C., H.H.H., S.G.,
Sen Chen, Z.Y., Y.G., M.W.C., J.Z., and M.A. performed experiments and
analyzed data. Shaoyong Chen, Y.W., E.M., and R.S. provided advice and
helped plan experiments. C.C., H.H.H., and S.P. wrote the manuscript. All
authors discussed the results and commented on the manuscript.
ACKNOWLEDGMENTS
Supported by grants from NIH (K99 CA166507 to C.C., K99 CA172948-01 to
H.H.H., R01 GM099409 to X.S.L., P01 CA163227, and SPORE in Prostate
Cancer P50 CA090381), and DOD (W81XWH-11-1-0295 and W81XWH-13-
1-0266 to S.P.B., W81XWH-10-1-0557 to H.H.H., W81XWH-13-PCRP-PTA
to Y.G., W81XWH-12-PCRP-PTA and W81XWH-13-PCRP-EHDA to Z.Y.), a
DF/HCC Mazzone Impact Award, and by Awards from the Prostate Cancer
Foundation.
Received: January 16, 2014
Revised: October 22, 2014
Accepted: November 6, 2014
Published: December 4, 2014
REFERENCES
Andreu-Vieyra, C., Lai, J., Berman, B.P., Frenkel, B., Jia, L., Jones, P.A., and
Coetzee, G.A. (2011). Dynamic nucleosome-depleted regions at androgen re-
ceptor enhancers in the absence of ligand in prostate cancer cells. Mol. Cell.
Biol. 31, 4648–4662.
Cai, C., He, H.H., Chen, S., Coleman, I., Wang, H., Fang, Z., Chen, S., Nelson,
P.S., Liu, X.S., Brown, M., and Balk, S.P. (2011). Androgen receptor gene
expression in prostate cancer is directly suppressed by the androgen recep-
tor through recruitment of lysine-specific demethylase 1. Cancer Cell 20,
457–471.
Carroll, J.S., Liu, X.S., Brodsky, A.S., Li, W., Meyer, C.A., Szary, A.J.,
Eeckhoute, J., Shao, W., Hestermann, E.V., Geistlinger, T.R., et al. (2005).
Chromosome-wide mapping of estrogen receptor binding reveals long-range
regulation requiring the forkhead protein FoxA1. Cell 122, 33–43.e treated with/out DHT for 24 hr and then immunoblotted as indicated.
oREST (G) or LSD1 (H) for 3 days in hormone-depleted medium, followed by
e also Figure S4.
hors
Cho, H.S., Suzuki, T., Dohmae, N., Hayami, S., Unoki, M., Yoshimatsu, M.,
Toyokawa, G., Takawa, M., Chen, T., Kurash, J.K., et al. (2011). Demethylation
of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle
progression in cancer cells. Cancer Res. 71, 655–660.
de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Chi,
K.N., Jones, R.J., Goodman, O.B., Jr., Saad, F., et al.; COU-AA-301 Investiga-
tors (2011). Abiraterone and increased survival in metastatic prostate cancer.
N. Engl. J. Med. 364, 1995–2005.
Garcia-Bassets, I., Kwon, Y.S., Telese, F., Prefontaine, G.G., Hutt, K.R.,
Cheng, C.S., Ju, B.G., Ohgi, K.A., Wang, J., Escoubet-Lozach, L., et al.
(2007). Histone methylation-dependent mechanisms impose ligand depen-
dency for gene activation by nuclear receptors. Cell 128, 505–518.
Gaughan, L., Stockley, J., Wang, N., McCracken, S.R., Treumann, A.,
Armstrong, K., Shaheen, F., Watt, K., McEwan, I.J., Wang, C., et al. (2011).
Regulation of the androgen receptor by SET9-mediated methylation. Nucleic
Acids Res. 39, 1266–1279.
Green, S.M., Mostaghel, E.A., and Nelson, P.S. (2012). Androgen action and
metabolism in prostate cancer. Mol. Cell. Endocrinol. 360, 3–13.
He, H.H., Meyer, C.A., Shin, H., Bailey, S.T., Wei, G., Wang, Q., Zhang, Y., Xu,
K., Ni, M., Lupien, M., et al. (2010). Nucleosome dynamics define transcrip-
tional enhancers. Nat. Genet. 42, 343–347.
He, H.H., Meyer, C.A., Chen, M.W., Jordan, V.C., Brown, M., and Liu, X.S.
(2012). Differential DNase I hypersensitivity reveals factor-dependent chro-
matin dynamics. Genome Res. 22, 1015–1025.
Hu, Q., Kwon, Y.S., Nunez, E., Cardamone, M.D., Hutt, K.R., Ohgi, K.A.,
Garcia-Bassets, I., Rose, D.W., Glass, C.K., Rosenfeld, M.G., and Fu, X.D.
(2008). Enhancing nuclear receptor-induced transcription requires nuclear
motor and LSD1-dependent gene networking in interchromatin granules.
Proc. Natl. Acad. Sci. USA 105, 19199–19204.
Huang, J., Sengupta, R., Espejo, A.B., Lee, M.G., Dorsey, J.A., Richter, M.,
Opravil, S., Shiekhattar, R., Bedford, M.T., Jenuwein, T., and Berger, S.L.
(2007). p53 is regulated by the lysine demethylase LSD1. Nature 449, 105–108.
Ko, S., Ahn, J., Song, C.S., Kim, S., Knapczyk-Stwora, K., and Chatterjee, B.
(2011). Lysine methylation and functional modulation of androgen receptor
by Set9 methyltransferase. Mol. Endocrinol. 25, 433–444.
Kontaki, H., and Talianidis, I. (2010). Lysine methylation regulates E2F1-
induced cell death. Mol. Cell 39, 152–160.
Lee, M.G., Wynder, C., Cooch, N., and Shiekhattar, R. (2005). An essential
role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature
437, 432–435.
Lupien, M., Eeckhoute, J., Meyer, C.A., Wang, Q., Zhang, Y., Li, W., Carroll,
J.S., Liu, X.S., and Brown, M. (2008). FoxA1 translates epigenetic signatures
into enhancer-driven lineage-specific transcription. Cell 132, 958–970.
Metzger, E., Wissmann, M., Yin, N., Mu¨ller, J.M., Schneider, R., Peters, A.H.,
Gu¨nther, T., Buettner, R., and Schu¨le, R. (2005). LSD1 demethylates repres-
sive histone marks to promote androgen-receptor-dependent transcription.
Nature 437, 436–439.
Metzger, E., Yin, N., Wissmann, M., Kunowska, N., Fischer, K., Friedrichs, N.,
Patnaik, D., Higgins, J.M., Potier, N., Scheidtmann, K.H., et al. (2008).
Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin
mark for transcriptional regulation. Nat. Cell Biol. 10, 53–60.
Metzger, E., Imhof, A., Patel, D., Kahl, P., Hoffmeyer, K., Friedrichs, N., Mu¨ller,
J.M., Greschik, H., Kirfel, J., Ji, S., et al. (2010). Phosphorylation of histone
H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 464,
792–796.
Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de Souza,
P., Fizazi, K., Mainwaring, P., Piulats, J.M., Ng, S., et al.; COU-AA-302 Inves-Cell Retigators (2013). Abiraterone in metastatic prostate cancer without previous
chemotherapy. N. Engl. J. Med. 368, 138–148.
Sahu, B., Laakso, M., Ovaska, K., Mirtti, T., Lundin, J., Rannikko, A., Sankila,
A., Turunen, J.P., Lundin, M., Konsti, J., et al. (2011). Dual role of FoxA1 in
androgen receptor binding to chromatin, androgen signalling and prostate
cancer. EMBO J. 30, 3962–3976.
Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., deWit,
R., Mulders, P., Chi, K.N., Shore, N.D., et al.; AFFIRM Investigators (2012).
Increased survival with enzalutamide in prostate cancer after chemotherapy.
N. Engl. J. Med. 367, 1187–1197.
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., Casero,
R.A., and Shi, Y. (2004). Histone demethylation mediated by the nuclear amine
oxidase homolog LSD1. Cell 119, 941–953.
Shi, Y.J., Matson, C., Lan, F., Iwase, S., Baba, T., and Shi, Y. (2005). Regulation
of LSD1 histone demethylase activity by its associated factors. Mol. Cell 19,
857–864.
Wang, J., Scully, K., Zhu, X., Cai, L., Zhang, J., Prefontaine, G.G., Krones, A.,
Ohgi, K.A., Zhu, P., Garcia-Bassets, I., et al. (2007a). Opposing LSD1 com-
plexes function in developmental gene activation and repression programmes.
Nature 446, 882–887.
Wang, Q., Li, W., Liu, X.S., Carroll, J.S., Ja¨nne, O.A., Keeton, E.K., Chinnaiyan,
A.M., Pienta, K.J., and Brown, M. (2007b). A hierarchical network of transcrip-
tion factors governs androgen receptor-dependent prostate cancer growth.
Mol. Cell 27, 380–392.
Wang, J., Hevi, S., Kurash, J.K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W.,
Chang, H., Xu, G., et al. (2009a). The lysine demethylase LSD1 (KDM1) is
required for maintenance of global DNAmethylation. Nat. Genet. 41, 125–129.
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R.,
Wang, H., Lupien, M., et al. (2009b). Androgen receptor regulates a distinct
transcription program in androgen-independent prostate cancer. Cell 138,
245–256.
Wang, D., Garcia-Bassets, I., Benner, C., Li, W., Su, X., Zhou, Y., Qiu, J., Liu,
W., Kaikkonen, M.U., Ohgi, K.A., et al. (2011). Reprogramming transcription
by distinct classes of enhancers functionally defined by eRNA. Nature 474,
390–394.
Wang, S., Sun, H., Ma, J., Zang, C., Wang, C., Wang, J., Tang, Q., Meyer, C.A.,
Zhang, Y., and Liu, X.S. (2013). Target analysis by integration of transcriptome
and ChIP-seq data with BETA. Nat. Protoc. 8, 2502–2515.
Wissmann, M., Yin, N., Mu¨ller, J.M., Greschik, H., Fodor, B.D., Jenuwein, T.,
Vogler, C., Schneider, R., Gu¨nther, T., Buettner, R., et al. (2007). Cooperative
demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent
gene expression. Nat. Cell Biol. 9, 347–353.
Yatim, A., Benne, C., Sobhian, B., Laurent-Chabalier, S., Deas, O., Judde,
J.G., Lelievre, J.D., Levy, Y., and Benkirane, M. (2012). NOTCH1 nuclear
interactome reveals key regulators of its transcriptional activity and oncogenic
function. Mol. Cell 48, 445–458.
You, A., Tong, J.K., Grozinger, C.M., and Schreiber, S.L. (2001). CoREST is
an integral component of the CoREST- human histone deacetylase complex.
Proc. Natl. Acad. Sci. USA 98, 1454–1458.
Yu, J., Yu, J., Mani, R.S., Cao, Q., Brenner, C.J., Cao, X., Wang, X., Wu, L., Li,
J., Hu, M., et al. (2010). An integrated network of androgen receptor,
polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
Cancer Cell 17, 443–454.
Yuan, X., Cai, C., Chen, S., Yu, Z., and Balk, S.P. (2014). Androgen receptor
functions in castration-resistant prostate cancer and mechanisms of resis-
tance to new agents targeting the androgen axis. Oncogene 33, 2815–2825.ports 9, 1618–1627, December 11, 2014 ª2014 The Authors 1627
